Publications by authors named "Mari Ariyasu"

Claim this Profile
L
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.
Masaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, Takeshi Inoue, Yujiro Kidani, Mari Ariyasu

Front Immunol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study.
John S Bradley, Elaine Orchiston, Simon Portsmouth, Mari Ariyasu, Takamichi Baba

Pediatr Infect Dis J· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection].
Yoshinori Yamano, Ippei Morita, Mari Ariyasu

Nihon Yakurigaku Zasshi· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
Vu Dinh Thiem, Pham Thi Van Anh, Chu Van Men, Do Thai Hung, Andrew J Pollard, Mari Ariyasu

Vaccine· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Satoshi Iwata, Andrew J Pollard, Yukio Tada, Shinya Omoto, Risa Y Shibata, Mari Ariyasu

Sci Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.
Takuhiro Sonoyama, Akari Kamitani, Risa Y Shibata, Naomi M Seki, Shinya Omoto, Mari Ariyasu

Vaccine X· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Takuhiro Sonoyama, Satoshi Iwata, Masaharu Shinkai, Naoko Iwata-Yoshikawa, Nozomi Shiwa-Sudo, Mari Ariyasu

Vaccine· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Yokokawa Shibata, Naomi M Seki, Mari Ariyasu

Vaccine· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
Satoshi Iwata, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Tomoyuki Homma, Mari Ariyasu

Vaccine· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Matteo Bassetti, Roger Echols, Yuko Matsunaga, Mari Ariyasu, Yohei Doi

Lancet Infect Dis· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Richard G Wunderink, Yuko Matsunaga, Mari Ariyasu, Philippe Clevenbergh, Roger Echols

Lancet Infect Dis· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance.
Roger Echols, Mari Ariyasu, Tsutae Den Nagata

Clin Infect Dis· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.
Matteo Bassetti, Mari Ariyasu, Bruce Binkowitz, Tsutae Den Nagata, Roger M Echols

Infect Drug Resist· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
Jonathan D Edgeworth, Domenico Merante, Sanjay Patel, Christopher Young, Paul Jones, Mari Ariyasu

Clin Infect Dis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Simon Portsmouth, David van Veenhuyzen, Roger Echols, Mitsuaki Machida, Juan Camilo Arjona Ferreira, Mari Ariyasu

Lancet Infect Dis· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by and .
Bin Cai, Roger Echols, Glenn Magee, Juan Camilo Arjona Ferreira, Gareth Morgan, Mari Ariyasu

Open Forum Infect Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Criteria for safety evaluation of antimicrobial agents.

J Infect Chemother· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis